Dipyridamole and adenosinergic pathway in Covid-19: a juice or holy grail

Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Engy Elekhnawy and Gaber El-Saber Batiha

Abstract

Background: Coronavirus disease 2019 (Covid-19) is an infectious worldwide pandemic triggered by severe acute respiratory coronavirus 2 (SARS-CoV-2). This pandemic disease can lead to pro-inflammatory activation with associated acute lung injury and acute respiratory distress syndrome.

Main body of the abstract: SARS-CoV-2 infection is linked with inhibition of adenosine and activation of phosphodiesterase. Dipyridamole (DIP) is a nucleoside transport and phosphodiesterase inhibitor so that it may potentially affect SARS-CoV-2 infection and its accompanying inflammations. Therefore, the primary objective of this mini-review study was to elucidate the potential beneficial impacts of DIP on the adenosinergic pathway in Covid-19. A systemic search was done using online databases with relevant keywords. The findings of the present study illustrated that DIP directly or indirectly, through augmentation of adenosine and inhibition of phosphodiesterase, mitigates Covid-19 outcomes.

Conclusion: Our study concluded that DIP has a potential therapeutic effect in the management and treatment of Covid-19. This could be attained either directly, through anti-SARS-CoV-2, anti-inflammatory, and anti-platelets properties, or indirectly, through augmentation of extracellular adenosine, which has anti-inflammatory and immune-regulatory effects. However, extensive randomized clinical trials, and clinical and prospective research in this area are required to demonstrate the safety and therapeutic efficacy of DIP and adenosine modulators in the treatment of Covid-19.

Keywords: ALI, Adenosine, ARDS, SARS-CoV-2, NLRP3, Phosphodiesterase

Background

Coronavirus disease 2019 (Covid-19) is a recent worldwide infection that was recognized for the first time in late December 2019 in Wuhan, China [1], triggered by severe acute respiratory coronavirus 2 (SARS-CoV-2). This disease may lead to critical instabilities systemically, including pro-inflammatory activation, cytokine storm, and associated damage to various organs [2]. Covid-19 affects various body systems, predominantly the respiratory system. The main presentation of the disease is acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Besides, acute kidney, pancreatic, and cardiac injury, neurological disorders, and endothelial dysfunction might occur as extra-pulmonary manifestations [3]. These multiple impacts of Covid-19 are attributed to the presence of angiotensin-converting enzyme 2 (ACE2), a receptor for SARS-CoV-2, on the cells of multiple organs, which facilitates its entry into various host cells [3, 4]. ACE2 receptor is principally articulated in the lung alveolar cells type II and proximal renal tubules. When SARS-CoV-2 binds to the ACE2, these defending receptors will be down-regulated. Consequently, the level of vasoconstrictors angiotensin II (Ang II) would increase, and the vasodilator angiotensin (Ang 1–7) (Ang 1–9)
would decrease, accompanied by the production of the pro-inflammatory cytokines [5].

Dipyridamole (DIP) is a nucleoside transport and phosphodiesterase (PDE) inhibitor that is used as an anti-platelet agent [6]. The primary mechanisms of DIP are inhibition of adenosine reuptake in the red blood cells (RBCs), platelets, and endothelial cells, as well as inhibition of PDE. DIP has diverse clinical effects. It reduces pulmonary hypertension, improves coronary blood flow, myocardial function and perfusion, mild peripheral vasodilator effect, and endothelial functions by inhibiting the discharge of the pro-inflammatory cytokines and preventing the sub-endothelial thrombogenicity.

As well, SARS-CoV-2 infection is usually interrelated with inhibition of adenosine (AD) as well as activation of PDE [7]. Since Covid-19 is linked with cardiovascular complications and coagulopathy, the main target of our mini-review study was to elucidate the potential impacts of DIP on the adenosinergic pathway in Covid-19.

Adenosinergic pathway and DIP in Covid-19

It is known that AD is a primary nucleoside for building RNA and DNA, and it has different derivatives, including adenosine monophosphate (AMP), adenosine diphosphate (ADP), and adenosine triphosphate (ATP). These derivatives act as signal transductions for the modulation of different physiological processes. AD acts on the specific receptors subtypes, including A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub> broadly found in different tissues. It acts as a cytoprotective signal against tissue injury. AD has immunosuppressive and anti-inflammatory effects (A<sub>2A</sub>, A<sub>2B</sub>) and is upregulated during ischemia and tissue hypoxia [8].

Cellular AD concentration is controlled by specific regulators, which are adenosine kinase (ADK), adenosine deaminase (ADA), and equilibrative nucleoside transporter-1 (ENT-1). ADA metabolizes AD to inosine when AD is present at a higher concentration owing to its low binding capacity. At the same time, ADK metabolizes AD, at baseline concentration, to 5-inosine monophosphate due to its higher affinity and capacity [9, 10]. In addition, ADA regulates the expression of ADA-binding protein (ADA-BP) on CD26 and dipeptidyl peptidase 4 (DPP-4). Interestingly, besides to ACE2 receptor, which has a low expression in the lung, ADA-BP of DPP-4/CD26 is considered as a potential receptor for binding and entrance of SARS-CoV-2. Thus, ADA competes with SARS-CoV-2 for binding to ADA-BP. Moreover, ADA activators like pegadensate ADA or recombinant ADA have been effectively used in the management of the human immunodeficiency virus (HIV) [11]. It has been proposed that ADA regulates and fine-tunes AD’s immunosuppressive and anti-inflammatory effects. Besides, the early administration of recombinant ADA attenuates the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) to its entry point, the DPP-4 receptor [12]. Since there is a 50% similarity in the genome sequence between SARS-CoV-2 and MERS-CoV, the recombinant ADA may minimize the severity of Covid-19 by inhibiting the binding between SARS-CoV-2 and DPP-4 [13]. Therefore, DPP-4 inhibitors may diminish SARS-CoV-2 pathogenesis and Covid-19 severity in diabetic people via modulation of SARS-CoV-2 entry and the accompanied inflammations [14]. Expressions of DPP-4 receptors are higher in patients with diabetes mellitus, nicotine smoking, chronic obstructive pulmonary disease (COPD), and obesity. This issue might explain the susceptibility of Covid-19 patients to the development of ALI and ARDS [15].

DIP doesn’t affect ADA activity or expression of ADA-BP; however, a higher intra-lymphocytic concentration is linked with immune suppression in patients with chronic kidney diseases. Also, high interferon-gamma (INF-γ) activates ADA activity in patients with HIV, thus, both INF-γ and ADA are regarded as prognostic and diagnostic factors for disease severity [16]. Tan et al. [17] experimental study demonstrated that DIP reduces the discharge of the pro-inflammatory cytokines and activation of T cells via modulation of the AD pathway. Indeed, ADA activity is negatively correlated with DPP-4 activity [17]. Therefore, AD elevation by DIP may increase ADA activity, reducing DPP-4 expression and interaction with SARS-CoV-2. However, ADA might be a possible target for SARS-CoV-2, causing a significant reduction in the cellular concentration of AD and the development of ALI and ARDS. Alongside this suggestion, a preclinical study proposed that AD protects against ALI and ARDS in a mouse model [18].

Augmentation of AD through inhibition of ADA and ADK may enhance the clinical results in Covid-19 patients. This can be attained via its immunosuppressive and anti-inflammatory effects, especially in the late phase, to counteract the exaggerated immune response that usually occurs in this phase of the disease [19, 20]. However, the immunosuppressive effect mediated by AD may affect viral clearance and increase viral replication in the initial phase of infection as ADA controls the negative impact of AD on the immune cells and immune response [21].

It has been reported that ADA inhibitors like pentostatin improves ARDS and its associated chronic inflammatory reactions [22]. Besides, ADK inhibitors like idodotubercidin attenuate ALI and ARDS via inhibition of neutrophil migration and improvement of the lung capillary-alveolar barrier. Nevertheless, the preclinical studies didn’t recommend using ADK inhibitors due to the
dangerous adverse effects such as liver toxicity and cerebral hemorrhage [23, 24].

Furthermore, AD, through the A2A receptor, activates the regulatory T cell (T_{reg}), which regulates the immune response to hypoxia through the reduction of neutrophil infiltrations, cytokine production, and protein extravasations in the lung alveoli [25]. Similarly, AD, through activation of lung peroxisome proliferator-activated receptor gamma (PPARγ), attenuates lung inflammations and interstitial fluid accumulation with the improvement of the alveolar gas exchange [25]. AD, through the A2B receptor, constrains the discharge of the pro-inflammatory cytokines and chemokines in the lung during hypoxia and mechanical ventilation injury [26]. Consequently, through its immune-modulating effect, AD might be an efficient agent in managing Covid-19-induced ARDS. Falcone et al. [27] reported a case with Covid-19 and ARDS treated using standard therapy and oxygen (21%) mixed with AD. They noticed that within one month, there was a dramatic improvement in clinical and radiological outcomes of this patient. Likewise, a retrospective analysis reported by Correale et al. [28] showed that standard therapy and oxygen (21%) mixed with AD could substantially enhance the consequences of 14 Covid-19 patients suffering from ALI. Furthermore, a docking analysis study illustrated that AD has anti-SARS-CoV-2 by interfering with the main viral protease and its inhibition [29, 30]. Therefore, AD has a critical role in managing Covid-19 by suppressing SARS-CoV-2 and associated lung inflammations.

Of note, Covid-19 complications are linked with coagulopathy and thrombosis owing to endothelial dysfunction and platelet activation by SARS-CoV-2 as evident through the elevated D-dimer serum levels [31]. The reduction of AD during SARS-CoV-2 and cytokine storm is due to augmentation of the intracellular transport of AD through ENT-1. The reduction of AD contributes to platelet activation and thrombosis through the reduction of cAMP [32]. DIP inhibits ENT-1 and ENT-2, so the extracellular AD would be increased through attenuation of the intracellular transport. Elevation of the extracellular AD is linked with platelet inhibition via activation of cAMP, thus, it will reduce the risk of intravascular thrombosis [33, 34]. Previously, it has been shown that DIP attenuates ALI in experimental rats through modulation of the lung AD via blocking ENT-1 and ENT-2 pathways [35].

Besides, DIP, through inhibition of PDE3, may prevent coagulopathy and ALI in Covid-19 patients through modulation of platelet function and lung inflammation [34]. The interactions between DIP and AD in SARS-CoV-2 infection might be beneficial, as shown in Fig. 1.

Therefore, DIP, through modulation of the AD/PDE axis, has a critical contribution to the management of Covid-19. DIP inhibits the pro-inflammatory cytokines and lung inflammation during Covid-19. Also, DIP, through escalation of AD, leads to potent anti-inflammatory effects which participate in the reduction of cytokine storm and the associated ALI [36, 37]. Moreover, the important contribution of DIP to Covid-19 is correlated

![Adenosinergic pathway and the contribution of DIP in Covid-19. DIP inhibits SARS-CoV-2 replication, platelet activation, PDE, ENT-1, and macrophages activation with activation of AD. ADK and ADA metabolize AD. SARS-CoV-2 activates ADA-BP on DPP-4 and inhibits AD](image-url)
with its wide-spectrum potential antiviral effects [38]. Interestingly, docking studies revealed that DIP blocks SARS-CoV-2 main protease (Mpro), leading to attenuation of Covid-19 pneumonia [39, 40]. Liu et al. [41] showed that when DIP was administered in severely ill Covid-19 patients, it led to a significant clinical improvement with the reduction of D-dimer. Similarly, DIP improves immune recovery and inhibits thrombosis and coagulation disorders in cases having Covid-19 [41].

Into the bargain, activation of nod-like receptor pyrin 3 (NLRP3) inflammasome usually accompanies SARS-CoV-2 infection. This causes the discharge of interleukins (IL-1β and IL-18) and the development of ALI and ARDS. Thus, DIP, by blocking ENT-1 and ENT-2 pathways, may reduce NLRP3 inflammasome-mediated ALI and ARDS [42]. In addition, DIP down-regulates inflammatory signaling pathway such as NF-κB, matrix metalloproteinase (MMP1, MMP9), and cyclooxygenase-2 (COX-2). This can be accomplished by suppressing the macrophage-1 gene (Mac-1) [43], which is enormously activated in Covid-19 infection. It has been proposed that COX-2 inhibitors have a remarkable outcome in the management of Covid-19 by reduction of lung inflammation and IL-6 [44]. Similarly, MMPs inhibitors like aprotenin reduce the pro-inflammatory cytokines-mediated ALI and ARDS [45, 46].

Renin-angiotensin system (RAS) is highly affected in Covid-19 owing to the down-regulation of ACE2 and interconnected with the progress of ALI, ARDS, and injury in multiple organs [47]. It has been reported recently that DIP reduces RAS and circulating AngII serum levels through an AD-dependent pathway [46, 47] or PDE inhibition pathway [48, 49]. Furthermore, DIP also mitigates Covid-19-induced complications like acute kidney injury [50], acute coronary syndrome [51], acute brain injury [52], and cytokine storm-mediated multi-organ injury [53, 54].

Therefore, this study highlighted that DIP has potential pleiotropic effects (Fig. 2) that mitigate SARS-CoV-2 infection and the accompanying extra-pulmonary disorders. Thereby, DIP might be a "Holy Grail" for Covid-19 patients who are severely ill.

**Conclusion**

Hence, DIP has a possible therapeutic impact in the managing of Covid-19. This effect can be achieved either directly, through anti-SARS-CoV-2, anti-inflammatory, and anti-platelets consequences, or indirectly, through augmentation of the extracellular AD, which has immune-regulatory and anti-inflammatory outcomes. However, extensive randomized clinical trials and clinical and prospective studies are necessary to declare the safety and clinical effectiveness of DIP and AD modulators in the management of Covid-19.

**Abbreviations**

ACE2: Angiotensin-converting enzyme 2; AD: Adenosine; ADA: Adenosine deaminase; ADA-BP: Adenosine deaminase-binding protein; ADK: Adenosine kinase; ADP: Adenosine diphosphate; ALI: Acute lung injury; AMP: Adenosine monophosphate; AngII: Angiotensin II; ARDS: Acute respiratory distress syndrome; AngPT2: Angiopoietin 2; ATP: Adenosine triphosphate; COPD: Chronic obstructive pulmonary disease; COX-2: Cyclooxygenase-2; COVID-19: Coronavirus disease 2019; DIP: Dipyridamole; DPP-4: Dipeptidyl dipeptidase 4; ENT: Equilibrative nucleoside transporter; HIV: Human immunodeficiency virus; IL: Interleukins; INF-γ: Interferon-γ; RAS: Renin-angiotensin system; RBCs: Red blood cells; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; Treg: Regulatory T cell; MERS-CoV: Middle east respiratory syndrome coronavirus; MMP: Metalloproteinase; NLRP3: Nod-like receptor pyrin 3; PPARγ: Peroxisome proliferator-activated receptor gamma; PDE: Phosphodiesterase.
Author contributions
HMA-K, A-A-G, EE, and GEB contributed to the study conception, design, material preparation, data collection, data analysis, and writing the first draft. All authors read and approved the final manuscript.

Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Availability of data and materials
All data are involved in the manuscript.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors have no relevant financial or non-financial interests to disclose.

Author details
1 Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriyah University, Baghdad 14132, Iraq. 2 Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt. 3 Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, Al Beheira, Egypt.

Received: 1 June 2022   Accepted: 16 September 2022

Published online: 23 September 2022

References
1. Al-Kuraishy HM, Al-Naimi MS, Lungeier CM, Al-Gareeb AI (2020) Macrolides and COVID-19: An optimum premise. Biomed Biotechnol Res J (BBU) 4:189
2. Dousari AS, Moghadam MT, Satarzadeh N (2020) COVID-19 (Coronavirus disease 2019): a new coronavirus disease. Infect Drug Resist 13:2819
3. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, Hou C, Wang H, Liu J, Yang D (2020) Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 24:1–10
4. Zhang H, Penninger JM, Li Y, Zhong N, Slutsy AS (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46:586–590
5. Bank S, De SK, Bankura B, Maiti S, Das M, Khan GA (2021) ACE/A2C balance might be instrumental to explain the certain comorbidities leading to severe COVID-19 cases. Biosci Rep 41
6. Bakola V, Karakozakii V, Tsiaplα A, Pappa F, Moutsios I, Pavlidou E, Logothetis S (2018) Dipyridamole-loaded biodegradable PLA nanoplatforms as coatings for cardiovascular stents. Nanotechnology 29:275101
7. Lakka L, Naka KK, Bechloulis A, Girds I, Duni A, Koutlas V, Moustaki M, Katoureas CS, Dounoumi E, Michalis LK (2020) The prognostic role of myocardial strain indices and dipyridamole stress test in renal transplantation patients. Echocardiography 37:62–70
8. Draper-Joyce CJ, Khoshouei M, Thal DM, Liang Y-L, Nguyen AT, Fumess SG, Venugopal H, Baltos J-A, Plitzko JM, Daney R (2018) Structure of the adenosine-bound human adenosine A1 receptor–Gi complex. Nature 558:S59–S63
9. Elekhnawy E, Sonboli F, Abdelaziz A, Elbanna T (2021) An investigation of the impact of triclosan adaptation on proteus mirabilis clinical isolates from an Egyptian university hospital. Braz J Microbiol 52:927–937
10. Geiger JD, Khan N, Murugan M, Boson D (2020) Possible role of adenosine in COVID-19 pathogenesis and therapeutic opportunities. Front Pharmacol 11:594487
11. Elefteriou P, Amanatidou D, Petrou A, Geronikaki A (2020) In silico evaluation of the effectivity of approved protease inhibitors against the main protease of the novel SARS-CoV-2 virus. Molecules 25:2529
12. Raj VS, Smits SL, Provacia LB, van den Brand JM, Wiersma L, Ouwendijk WJ, Besterbroek TM, Spronken MI, van Amerongen G, Rottier PJ (2014) Adenosine deaminase acts as a natural antagonist for dipeptidyl peptide 4-mediated entry of the middle east respiratory syndrome coronavirus. J Virol 88:1834–1838
13. Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, Dhama K, Yatoo MI, Bonilla-Aldana DK, Rodriguez-Morales AJ (2020) SARS-CoV-2, SARS-CoV, and MERS-CoV: a comparative overview. Infec Med 28:174–184
14. Du H, Wang DW, Chen C (2020) The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients. J Cell Mol Med 24:10274–10278
15. Solerte SB, Di Sabatino A, Galli M, Fiorina P (2020) Dipeptidyl peptide-4 (DPP4) inhibition in COVID-19. Acta Diabetol 57:779–783
16. Hu X, Xing B, Wang W, Yang F, Sun Y, Zheng X, Shang Y, Chen F, Liu N, Yang L (2020) Diagnostic values of Xpert MTB/RIF, T-SPOT. TB and adenosine deaminase for HIV-negative tuberculous pericarditis in a high burden setting: a prospective observational study. Sci Rep 10:1–10
17. Tan MX, Hing TY, Mak A (2019) The potential use of metformin, dipyridamole, N-acetylcysteine and statins as adjunctive therapy for systemic lupus erythematosus. Cells 8:823
18. Kahraman S, Altinova AE, Elgun S, Yalcin MM, Yilmaz BA, Ozkan C, Akturk M, Torunar FB (2019) Serum activities of dipeptidyl peptide-4 and adenosine deaminase in polycystic ovary syndrome: association with obesity. Gynecol Endocrinol 35:714
19. Abouelelkhir MA (2020) Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: a hypothesis. Med Hypotheses 144:110012
20. Olugbodi JO, Okleye MT, Mostafa-Hedebag G, Alqarni M, Ilesanmi OB, Battha GE-S, Akinnmoladun AC (2022) Glyphaeas C-enriched extract of glyphaea brevis restored the antioxidant and reproductive integrity of 1, 4-dinitrobenzene-intoxicated rats. Biomed Photocarbor 145:112359
21. Herrera-Calderon O, Chacaltana-Ramos LJ, Huyanaca-Gutiérrez C, Alqarni M, Alqarni M, Battha GE-S (2021) Chemical constituents, in vitro antioxidative and anti-inflammation activity and in silico study on NADPH oxidase of Allium sativum L. (Garlic) essential oil. Antioxidants 10:1844
22. Kempen S, Sun Z, Kay NE, Paetta EM, Maziya JJ, Ketterling RP, Frankurt O, Claxton DF, Saltzman JN, Svrkalo G (2019) Pentostatin, cyclophosphamide, and rituximab followed by alemtuzumab for relapsed or refractory chronic lymphocytic leukemia: a phase 2 trial of the ECOG-acrin cancer research group (E2903). Acta Haematol 142:224–232
23. Caetano D, Gonçalves Lima CM, Lima A, Faria Silva D, De Souza Hassiemer G, Veiruck S, Gregorio SR, Da Silva GA, De Cassia Franco RJ, Xavier Courtrim M (2022) Chemical fingerprint of non-aged artisanal sugarcane spirits using Kohonen artificial neural network. Food Anal Methods 15:890–907
24. Onikanni AS, Lawal B, Oluosola AO, Olugbodi JO, Sani S, Ajiboye BO, Ilesanmi OB, Alqarni M, Mostafa-Hedebag G, Obaidullah AJ (2021) Sterculia tragacantha linde leaf extract ameliorates STZ-induced diabetes, oxidative stress, inflammation and neuronal impairment. J Inflamm Res 14:6749
25. He X, Ju J-L, Li J, Zhao L, Zhang Y, Zeng Y-J, Dai S-S, He F-T (2013) A feedback loop in PPARY–adenosine A2A receptor signaling inhibits inflammation and attenuates lung damages in a mouse model of LPS-induced acute lung injury. Cell Signal 25:1913–1923
26. Hoegl S, Brodsky KS, Blackburn MR, Karmouty-Quintana H, Zwissler B, Eltzschig HK (2015) Alveolar epithelial A2B adenosine receptors in pulmonary acute lung injury. Cell Signal 25:1913–1923
27. Mario G, Cinquegnale CS, D’Emidio M, Pizzuti T, Di Gaudio A, Mancini E (2020) The role of the angiotensin-2 (ACE2) receptor in the COVID-19 pandemic. J Infect 80:554–563
28. Falcone R, Coi F, Fichert S, Sapienza A, Castelfranchi C, Paglieri F (2020) All we need is trust: How the COVID-19 outbreak reconfigured trust in Italian public institutions. Front Psychol 11:561747
29. Correale P, Caracciolo M, Bilotta F, Conte M, Cuzzola M, Falcone C, Mangano C, Falzea AC, Iuliano E, Morabito A, Foti G (2020) Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia. PLoS One, 15(10):e0239692
30. Venugopal PP, Chakraborty D (2020) Molecular mechanism of inhibition of COVID-19 main protease by β-adrenoceptor agonists and adenosine deaminase inhibitors using in silico methods. J Biomol Struct Dyn 1–16.
